Development of improved pertussis vaccine by Rumbo, Martín & Hozbor, Daniela Flavia
©
20
14
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
Human Vaccines & Immunotherapeutics 10:8, 2450–2453; August 2014; © 2014 Landes Bioscience
 CommentAry
2450 Human Vaccines & Immunotherapeutics Volume 10 Issue 8
CommentAry
Rates of infection with Bordetella pertussis, the gram-negative bacterium 
that causes the respiratory disease called 
whooping cough or pertussis, have not 
abated and 16 million cases with almost 
200,000 deaths are estimated by the 
WHO to have occurred worldwide in 
2008. Despite relatively high vaccination 
rates, the disease has come back in recent 
years to afflict people in numbers not 
seen since the pre-vaccine days. Indeed, 
pertussis is now recognized as a frequent 
infection not only in newborn and 
infants but also in adults. The disease 
symptoms also can be induced by the 
non-vaccine-preventable infection with 
the close species B. parapertussis for 
which an increasing number of cases 
have been reported. The epidemiologic 
situation and current knowledge of the 
limitations of pertussis vaccine point out 
the need to design improved vaccines. 
Several alternative approaches and their 
challenges are summarized.
Pertussis or whooping cough is a highly 
contagious vaccine-preventable respiratory 
disease. All age groups are susceptible to 
pertussis infection; however the disease 
is more severe in unvaccinated infants 
in whom potentially fatal complications 
such as convulsions, bronchopneumonia 
and encephalopathy can occur. The gram-
negative bacteria B. pertussis is the main 
disease-causing agent. However, the 
closely related species B. parapertussis also 
can induce these symptoms, as has been 
reported in increasing numbers.1,2
For several decades, infant 
immunization programs with pertussis 
vaccines have been very successful in 
preventing severe disease.3,4 However, in 
recent years the disease has reemerged in 
many communities/states/countries with 
a surprisingly high number of cases.5-9 The 
global pertussis burden estimated in 2008 
by the WHO is ~16 million cases and 
195,000 deaths per year, with the highest 
incidence rates and major risk of deaths 
and complications occurring in infants.10 
In Argentina, the number of reported 
cases has increased steadily since 2002. 
The number of cases reported in 2011 
quadrupled from those reported in 2008.11 
In 2011, 76 deaths were reported in < 1-y-
old children (www.snvs.msal.gov.ar). It is 
noteworthy that in developed countries 
like the US or Australia, the number of 
cases reported in 2010–2 at least tripled 
compared with those from a few years 
earlier.9,12-15
This alarming situation has moved 
the scientific community and health 
professionals to seek an understanding 
of this new situation. Several factors 
that could explain the resurgence of the 
disease have been proposed, most of them 
associated with current vaccines: waning 
vaccine-induced immunity, the switch 
from whole cell vaccines (wP) to acellular 
vaccines (aP) and pathogen adaptation.16 
The wP vaccines were developed and 
used since the 1950s in western countries, 
reaching almost worldwide application in 
the 1970s. The aP vaccines were developed 
because of concerns raised by reports of 
neurological and other adverse reactions 
in children upon wP administration. 
Because of such concerns and the lower 
rate of adverse effects caused by the aP 
vaccination compared with wP vaccines 
were gradually replaced in the 1980s and 
1990s by aP vaccines in some developed 
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countries.17 Beside the use of these 
vaccines, outbreaks of pertussis also were 
observed among vaccinated individuals 
within just a few years of vaccination.18 
This suggested that immunity from 
vaccination waned and that protection 
against the disease and infection was 
incomplete. In order to reinforce the 
defenses against the pathogen, in the last 
years several boosters have been included 
in national vaccination programs, 
including a universal booster dose with aP 
vaccine for preadolescents and a booster 
dose for pregnant women.19,20
The switch from wP to aP vaccines 
seems to have complicated the pertussis 
situation because immune responses 
elicited by aP vaccines are less robust. In 
a non-human model it was shown that aP 
vaccines protect against disease but fail 
to prevent infection and transmission.21 
A case-control clinical study designed to 
assess the risk of pertussis among 10- to 
17-y olds during the 2010–1 outbreak in 
California revealed that teenagers who had 
received four wP doses were nearly six times 
less likely to have been given a diagnosis 
of pertussis than those who had received 
all aP vaccines and nearly four times less 
likely than those who had received a mix 
of vaccines.22 Another study also found 
that the risk of pertussis was increased 
in schoolchildren and adolescents whose 
infant schedule was composed exclusively 
of aP doses compared with subjects who 
received ≥ 1 wP dose.23,24 These findings 
are consistent with the knowledge that 
aP vaccines elicit a mixed Th2/Th17 
response which is less effective than the 
strong Th1 response induced by natural 
infection or wP.25 This observation has 
been confirmed in a baboon model.26
In addition to waning of vaccine-
induced immunity, changes in the 
antigenic and genotypic characteristics of 
circulating B. pertussis strains are being 
described: alleles of vaccine antigens 
expressed by circulating bacteria largely 
differ from those expressed by the 
strains used in vaccine production.27 The 
emergence of these predominant strains 
seems to reflect selective pressure from 
vaccination. In some but not all countries, 
the emergence of allelic variants coincides 
with disease resurgence. More recently, 
strains have emerged that do not express 
one or more components of pertussis 
vaccines, in particular pertactin.28,29 It 
was reported in the US that pertactin-
deficient isolates increased by > 50% 
in 2012.30 Similarly in Australia where 
a large outbreak of pertussis occurred 
during 2008–12, it was detected that 
30% (96/320) of B. pertussis isolates did 
not express pertactin.31 Observations 
that pertactin-deficient isolates were only 
detected in regions where aP vaccines 
were the only vaccine used suggest that aP 
vaccination resulted in the expansion of 
strains that have a selective advantage in 
vaccinated human populations.
Other factors that also contributes 
to pertussis resurgence is the increased 
number of cases caused by B. parapertussis 
for which no available vaccines confer 
protection.32,33 Little attention has been 
paid to this bacterium because it causes a 
milder illness than B. pertussis and the rate 
of detection seems to be low. However, 
recent studies have revealed high rates of 
detection in patients with whooping cough 
in some field studies. Watanabe et al. 
revised the current literature, pointing out 
that it is necessary to pay greater attention 
to infections caused by this bacterium.33 
To this aim it is important to improve the 
specific diagnosis test for B. parapertussis.
Under this entire context it is clear that 
a new generation of vaccines capable of 
overcoming the weaknesses associated with 
the current vaccines is needed to improve 
disease control. Several pathways deserve 
to be explored even without there being 
a universal solution, since each country 
has a different situation depending on the 
history of vaccination policy developed 
in the last decades. One possibility is to 
promote the use of wP vaccines but with 
new less reactogenic34 and improved35 
formulations. However, the return to wP 
vaccine use would be difficult for the 
public to accept in countries that switched 
to aP vaccines due to adverse reactions 
from wP vaccines.
Another possibility is to improve aP 
vaccine by the inclusion of additional 
virulence factors of B. pertussis such as 
adenylate cyclase toxin or iron regulated 
proteins36,37 and/or an adjuvant able to 
drive a high Th1 response, i.e., Toll-like 
receptor agonists, as has been discussed 
recently.38
There are several new vaccine candidates 
that may contribute to solving the 
problem of the reemergence of pertussis. 
The use of an attenuated B. pertussis 
strain administered intranasally has been 
successfully tested in animal models 
and moved to Phase I clinical trials.39,40 
Although this is a promising application 
that has shown some advantages,41,42 it 
shares the potential safety concerns related 
to the use of attenuated pathogens.39
An interesting alternative that 
combines some of the above-mentioned 
strategies is the use of outer membrane 
vesicles, also called nanoparticles, which 
contain bacterial surface antigens. There 
are two meningitis vaccines containing 
components derived from the outer 
membrane and periplasm of Neisseria 
meningitides serogroup B.43 Data on 
safety and efficacy of these vaccines 
and the knowledge that the majority of 
Gram-negative bacteria secrete outer 
membrane vesicles may make vaccination 
strategy with outer nenbrane vesicles 
(or nanoparticles) feasible for other 
diseases.44 In this context, we designed 
an aP nanoparticle vaccine derived from 
B. pertussis and B. parapertussis, with 
protective effect in the accepted model 
of intranasal challenge in mice against 
different genetic background strains 
of B. pertussis and B. parapertussis.45-47 
This vaccine formulation has a safety 
profile in mice that is comparable 
to that of commercial aP and much 
better than wP. Furthermore, it elicits 
a protective immune response with a 
mixed Th1/Th2 profile and induces 
also a robust antibody response. We 
have characterized the composition of 
the pertussis nanoparticles, finding > 40 
protein components, mostly membrane-
bound proteins. The presence of a high 
number of immunogens in the vaccine 
formulation is important since this may 
avoid the excessive selective pressure 
conferred by a single or a few protective 
vaccine antigens.48 This formulation 
also is attractive economically, which 
is critical for its use in developing 
countries. It is estimated that the final 
cost per dose is less than that of existing 
aP formulations based on several purified 
protein immunogens, which impacts on 
the final cost of the vaccine. In our case 
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a single process step is necessary for the 
production of each B. pertussis and B. 
parapertussis nanoparticle.
In summary, evidence that the current 
aP vaccines are not providing optimal 
control of pertussis has enhanced the 
interest in improvements of current 
vaccines and in the development of new 
vaccines. Several options such as inclusion 
of new antigens or adjuvanting the current 
aP vaccine to change the Th profile are 
under debate. On the side of new vaccines, 
a live attenuated strain is a potential 
option. In this category, the formulation 
based on nanoparticles (outer membrane 
vesicles) of B. pertussis and B. parapertussis 
seems to be a good alternative to current 
formulations containing a greater number 
of immunogens that current aP vaccines 
and conformations close to those found 
in bacteria, favoring protective capacity. 
These formulations also provide protection 
against B. pertussis and B. parapertussis, 
extending the range of protection over 
current vaccines, which would contribute 
to better disease control. Tese different 
options are not mutually exclusive and 
may adapt differently to situations that are 
not similar due to the previous history of 
vaccination in the different countries.
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